McKinney, Brandon C. http://orcid.org/0000-0002-0663-7569
Lin, Huang
Ding, Ying
Lewis, David A. http://orcid.org/0000-0002-3225-6778
Sweet, Robert A. http://orcid.org/0000-0001-9154-9709
Article History
Received: 15 December 2016
Revised: 20 January 2017
Accepted: 6 March 2017
First Online: 23 March 2017
Competing interests
: D.A.L. currently receives investigator-initiated research support from Pfizer and in 2012–2014 served as a consultant in the areas of target identification and validation and new compound development to Autifony, Bristol–Myers Squibb, Concert Pharmaceuticals, and Sunovion. The remaining authors declare no competing interests.